Author + information
- Kenya Nasu,
- Yuji Oikawa,
- Yoshihiro Takeda,
- Masatoshi Suzuki,
- Yoshiaki Mibiki,
- Yuichi Ujiie,
- Masaki Tanabe,
- Takafumi Tsuji,
- Hiroshi Ohta,
- Shinichi Usui,
- Tadanori Aizawa and
- Takahiko Suzuki
Percutaneous coronary interventions involving small coronary vessels represent a true challenge because of the increased risk of restenosis and adverse outcomes. The aim of this study is to evaluate the one–year clinical results following small coronary stenting between everolimus– (EES) and paclitaxel–eluting stent (PES).
PLUM (PROMUS/Xience V Everolimus–ELUting Coronary Stent for sMall coronary artery disease: 264 patients with 279 lesions) and SACRA (SmAll CoronaRy Artery treated by TAXUS Liberté: 245 patients with 258 lesions) registries are prospective, multicenter registries to assess the efficacy of single EES and PES in patients with small coronary artery diseases. Inclusion criteria were 1) Lesions >75% diameter stenosis in vessels <2.5mm in diameter, 2) lesion length <28mm. The primary endpoint is clinical driven target lesion revascularization (TLR) rate at one year.
Major adverse cardiac events between the two groups were similar, however, one year TLR rate was significantly lower in EES group (Table).
EES showed better clinical and angiographic results for treatment of small coronary artery diseases.
One year clinical and angiographic results
|Acute gain, mm||1.37±0.36||1.40±0.29||0.2|
|Late loss, mm||0.24±0.29||0.50±0.46||<0.0001|
|Binary restenosis rate||5.0%||11.1%||0.02|
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.–10:45 a.m.
Session Title: Coronary Stents
Abstract Category: 47. TCT@ACC–i2: Coronary Intervention, Devices
Presentation Number: 2101–241
- 2013 American College of Cardiology Foundation